ClinicalTrials.gg
RecruitingNCT05399537Updated Oct 5, 2026

Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT

A Phase 3 interventional study of Prismocitrate 18 and PrisMax System Version 3.x with calcium line accessory in Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT) and Acute Kidney Injury (AKI), sponsored by Vantive Health LLC. Recruiting at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Vantive Health LLC (formerly part of Baxter Healthcare Corporation) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.
Updated Oct 5, 2026Site recruiting status changedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.

Planned enrollment
149th of 237
40 · median 67
Started
2024
with 23 others
Phase 3
20 of 370
3 open now
Primary completion
2027-01
later than 32 of 87 live
Registered
283rd of 370
by date

Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 149th largest by planned enrollment of the 237 interventional ones that give a count, is one of 24 that started in 2024, is one of 20 in phase 3, reaches primary completion later than 32 of the 87 other live ones, and was the 283rd registered.

Acute Kidney Injury

1,692 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 230 Acute Kidney Injury studies recruiting now, 162 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies in Acute Kidney Injury with a site in United States, or all of them as a file.
02

Study summary

Prismocitrate 18 is a continuous renal replacement therapy (CRRT) solution to be used as a renal replacement solution and as an anticoagulant to prevent blood clotting in the extracorporeal circuit. The delivery of CRRT therapy is provided by the PrisMax System which includes regional citrate anticoagulation (RCA) software to facilitate citrate and calcium compensation prescription.

The objectives of this study are: 1) to confirm the safety of Prismocitrate 18 in patients receiving CRRT using continuous venovenous hemodiafiltration (CVVHDF) or continuous venovenous hemofiltration (CVVH) and 2) to observe that the software and interface for the PrisMax System Version 3.x with calcium line accessory allows for implementation of regional citrate anticoagulation (RCA) (citrate and calcium dosing) during CRRT with Prismocitrate 18 and intended prescription.

The study period of the patient's CRRT will be up to 10 days.

03

Conditions studied

  • Regional Citrate Anticoagulation (RCA)
  • Continuous Renal Replacement Therapy (CRRT)
  • Acute Kidney Injury (AKI)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be ≥18 years of age
  • Patients who are candidates for CRRT
  • Patients expected to survive for at least 24 hours
  • Patients with a to heparin or an increased risk of hemorrhage
  • Patient and/or legally-authorized representative has signed a written form (ICF) per 21 CFR Part 50.55(e)

Exclusion criteria

Exclusion Criteria:

  • Patients with a known allergy to citrate or who have ever experienced an adverse reaction associated with citrate products, including patients with a prior history of citrate toxicity
  • Patients with acute liver failure, defined by the occurrence of encephalopathy and hepatic synthetic dysfunction within 26 weeks of the first symptoms of liver disease and without evidence of chronic liver disease
  • Patients with acute-on-chronic liver failure characterized by acute decompensation of cirrhosis and a Liver Failure Score >10
  • Patients with shock and associated lactic acidosis (lactate >4 mmol/L)
  • Patients with a systemic ionized calcium concentration outside the normal physiologic range (1.0 - 1.3 mmol/L), or outside of the laboratory reference range (Note: It is acceptable to provide calcium supplementation or treatment for hypercalcemia to achieve a normal physiologic range prior to therapy initiation)
  • Female patients of who are pregnant or breastfeeding. (Note: All female patients, who have not undergone a hysterectomy, bilateral oophorectomy with or without hysterectomy, or has medically documented ovarian failure before study Screening must have a negative serum beta human chorionic gonadotropic [B-hCG] pregnancy test at Screening)
  • Patients who are currently participating in another interventional clinical study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Prismocitrate 18 using the PrisMax System Version 3.x with calcium line accessory

    This is a single-arm study. Patients will receive regional citrate anticoagulation (RCA) with Prismocitrate 18 (investigational drug) during their CRRT treatment using the PrisMax System Version 3.x with calcium line accessory (investigational device).

    Drug: Prismocitrate 18 · Device: PrisMax System Version 3.x with calcium line accessory

Interventions

  • DrugPrismocitrate 18

    Prismocitrate 18 solution (investigational drug) will be used in pre-dilution mode only; the rate of administration depends on the targeted citrate dose and the prescribed flow rate. The pre-filter infusion rate of Prismocitrate 18 solution will be indexed to the blood flow rate (BFR) to achieve a target blood citrate concentration of 3 mmol/L of blood. The flow rate for the anticoagulation of the extracorporeal circuit will be titrated to achieve a post-filter concentration of iCa of 0.25 to 0.35 mmol/L.

  • DevicePrisMax System Version 3.x with calcium line accessory

    The RCA software on PrisMax System Version 3.x with calcium line accessory (investigational device) will be enabled to carefully guide the health practitioner for citrate dosing and calcium compensation.

06

What researchers measure

Primary outcomes

  1. Number of participants with symptomatic hypocalcemia related to Prismocitrate 18 administration

    Defined as symptomatic patients (e.g., tetany/spasms, seizures, or cardiac events secondary to a prolonged QT interval), with symptoms deemed attributable to hypocalcemia and with a confirmed systemic ionized calcium \< 0.9 mmol/L.

    Time frame: Day 1 up to Day 10

  2. Number of participants with symptomatic hypercalcemia related to Prismocitrate 18 administration

    Defined as symptomatic patients (e.g., changes in mental status not explained by the interventions or underlying conditions or cardiac events secondary to a shortened QT interval), with symptoms deemed attributable to hypercalcemia and with a confirmed systemic ionized calcium \> 1.4 mmol/L.

    Time frame: Day 1 up to Day 10

  3. Number of participants with symptomatic citrate accumulation related to Prismocitrate 18 administration

    Defined as symptomatic patients (e.g., refractory acidosis), with symptoms deemed attributable to citrate accumulation and with a systemic total calcium to ionized calcium ratio \> 2.5.

    Time frame: Day 1 up to Day 10

Secondary outcomes

  1. Number of participants with Adverse Events related to study product and/or procedure

    Incidence of AE and SAE's are also considered secondary outcome measures and will be reported in the Adverse Event section

    Time frame: Day 1 up to Day 28

  2. Delivery of regional citrate anticoagulation (RCA) therapy using PrisMax System Version 3.x

    Percentage of complete RCA treatments according to protocol

    Time frame: Day 1 up to Day 10

07

Study locations

7 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Sharing of Clinical Trial Data: The Sponsor is committed to sharing clinical trial data with external medical experts and scientific researchers in the interest of advancing public health. As such, the Sponsor will supply anonymized Individual Patient Datasets (IPD) and supporting documents (synopsis of clinical study reports, protocol and SAP's)

Supporting information: Study protocol, Statistical analysis plan

Time frame: Upon approval of a legitimate research request.

Access criteria: Research requests will be reviewed by qualified medical and scientific experts within the company. If the Sponsor agrees to the release of clinical data for research purposes, the requestor will be required to sign a data sharing agreement (DSA) in order to ensure protection of patient confidentiality and any intellectual property rights of the Sponsor prior to the release of any data

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jan 2027, 30 months after the start.

Of 35 phase 3 interventional studies under Acute Kidney Injury, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 63. This study's planned 30 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Dec 2026 → Jan 2027 and completion Dec 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2022
First posted
Jun 1, 2022
StartActual
Jul 12, 2024
Primary completionEst.
Jan 2027was Dec 2026
CompletionEst.
Jan 2027was Dec 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites changed recruiting status (3 now terminated, 2 now recruiting)
Show 5 sites
  • University of Michigan · Ann Arbor, United StatesNot yet recruiting→Recruiting
  • Bon Secours Mercy Health-Springfield Regional Medical Center · Springfield, United StatesActive, not recruiting→Terminated
  • VA Pittsburgh Healthcare System · Pittsburgh, United StatesActive, not recruiting→Terminated
  • Methodist Dallas Medical Center · Dallas, United StatesNot yet recruiting→Recruiting
  • Gamma Medical Research, Inc / McAllen Medical Center · McAllen, United StatesActive, not recruiting→Terminated
Oct 5, 2026
Primary completion
Dec 2026→Jan 2027
Oct 5, 2026
Study completion
Dec 2026→Jan 2027
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    5 sites changed recruiting status (3 now terminated, 2 now recruiting)
    Show 5 sites
    • University of Michigan · Ann Arbor, United StatesNot yet recruiting→Recruiting
    • Bon Secours Mercy Health-Springfield Regional Medical Center · Springfield, United StatesActive, not recruiting→Terminated
    • VA Pittsburgh Healthcare System · Pittsburgh, United StatesActive, not recruiting→Terminated
    • Methodist Dallas Medical Center · Dallas, United StatesNot yet recruiting→Recruiting
    • Gamma Medical Research, Inc / McAllen Medical Center · McAllen, United StatesActive, not recruiting→Terminated
    Primary completion Dec 2026→Jan 2027
    Study completion Dec 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05399537
Lead sponsor
Vantive Health LLC
Responsible party
Sponsor
First posted
Jun 1, 2022
Start date
Jul 12, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Global CORP Clinical Trials Disclosure
Contact
Global.CORP.ClinicalTrialsDisclosure@vantive.com
+1 2249484283

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion